fbpx Skip to main content

FRIDAY, Oct. 9, 2020 (HealthDay News) — Patients with type 2 diabetes (T2D) are more likely to develop vascular dementia and nonvascular dementia compared with controls without diabetes, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held virtually from Sept. 21 to 25.

Carlos Celis-Morales, Ph.D., from the University of Glasgow in the United Kingdom, and colleagues examined the extent to which T2D is associated with Alzheimer disease, vascular dementia, and nonvascular dementia incidence in a cohort including 378,299 patients with T2D and 1,886,022 matched controls. The researchers also assessed whether these associations differed according to glycemic control.

The researchers found that 5.7 percent of patients with T2D and 5.2 percent of controls developed dementia during a median follow-up of 6.8 years. The strongest association was seen for vascular dementia, with a hazard ratio (HR) of 1.36 for patients with T2D versus controls. The association of T2D with nonvascular dementia was more modest (HR, 1.08), while the risk for Alzheimer disease was lower for patients with T2D (HR, 0.92). There was a dose-response association when the analyses were stratified by circulating concentrations of hemoglobin A1c (HbA1c), with a higher risk for Alzheimer disease, vascular dementia, and nonvascular dementia in T2D with HbA1c >87 mmol/mol versus HbA1c <52 mmol/mol (HRs, 1.34, 1.93, and 1.67, respectively).

“With poor blood sugar control in individuals with type 2 diabetes being associated with an increased risk of developing vascular and nonvascular dementia, our findings underscore the importance of good blood sugar control,” Celis-Morales said in a statement.

Abstract No. 6
More Information

You May Also Like::  A Review of the Efficacy of Inebilizumab In Patients With NMOSD

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More